Key Points
- Andrew Callos sold 15,000 shares of Cytokinetics on Jan. 5 at an average of $60.28 for $904,200, leaving him with 50,440 shares valued at about $3.04 million (a 22.92% reduction in his position).
- The Jan. 5 sale continues a recent pattern of insider selling by Callos, including a Dec. 5 disposition of 52,486 shares for roughly $3.46 million and several smaller December/January sales.
- Analysts remain generally bullish on CYTK with an average price target of $83.61 (15 Buys, 3 Holds, 1 Sell) and recent target increases (e.g., HC Wainwright to $136, Morgan Stanley to $71); the stock has a $7.49 billion market cap and a 12‑month range of $29.31–$70.98.
Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) EVP Andrew Callos sold 15,000 shares of the stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $60.28, for a total transaction of $904,200.00. Following the transaction, the executive vice president directly owned 50,440 shares of the company's stock, valued at $3,040,523.20. The trade was a 22.92% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
Andrew Callos also recently made the following trade(s):
- On Friday, January 2nd, Andrew Callos sold 1,798 shares of Cytokinetics stock. The shares were sold at an average price of $62.62, for a total value of $112,590.76.
- On Monday, December 29th, Andrew Callos sold 1,809 shares of Cytokinetics stock. The stock was sold at an average price of $62.44, for a total value of $112,953.96.
- On Monday, December 8th, Andrew Callos sold 1,042 shares of Cytokinetics stock. The shares were sold at an average price of $65.96, for a total value of $68,730.32.
- On Friday, December 5th, Andrew Callos sold 52,486 shares of Cytokinetics stock. The stock was sold at an average price of $65.95, for a total value of $3,461,451.70.
Cytokinetics Price Performance
Shares of Cytokinetics stock opened at $61.26 on Tuesday. The stock has a market capitalization of $7.49 billion, a price-to-earnings ratio of -9.74 and a beta of 0.55. The business has a 50-day moving average of $63.60 and a 200 day moving average of $50.96. Cytokinetics, Incorporated has a 12 month low of $29.31 and a 12 month high of $70.98.
Cytokinetics (NASDAQ:CYTK - Get Free Report) last issued its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported ($1.54) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.59) by $0.05. The business had revenue of $1.94 million for the quarter, compared to analysts' expectations of $6.05 million. During the same quarter last year, the company earned ($1.36) earnings per share. The firm's revenue for the quarter was up 318.1% on a year-over-year basis. Equities research analysts anticipate that Cytokinetics, Incorporated will post -5.24 earnings per share for the current year.
Analysts Set New Price Targets
CYTK has been the subject of several research reports. Leerink Partners set a $83.00 price target on shares of Cytokinetics in a research note on Monday, December 22nd. HC Wainwright boosted their target price on Cytokinetics from $120.00 to $136.00 and gave the stock a "buy" rating in a research note on Monday, December 22nd. Morgan Stanley upped their price target on Cytokinetics from $65.00 to $71.00 and gave the stock an "overweight" rating in a report on Monday, December 22nd. Citizens Jmp lifted their price objective on Cytokinetics from $78.00 to $88.00 and gave the company a "market outperform" rating in a research note on Monday, December 22nd. Finally, UBS Group reissued a "neutral" rating and set a $61.00 price objective on shares of Cytokinetics in a research report on Monday, December 1st. Fifteen equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $83.61.
Check Out Our Latest Report on Cytokinetics
Hedge Funds Weigh In On Cytokinetics
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. EverSource Wealth Advisors LLC grew its position in shares of Cytokinetics by 723.7% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 766 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 673 shares during the last quarter. Quarry LP purchased a new position in shares of Cytokinetics during the third quarter worth about $30,000. Advisory Services Network LLC acquired a new stake in shares of Cytokinetics during the third quarter worth about $32,000. Johnson Financial Group Inc. purchased a new stake in shares of Cytokinetics in the 3rd quarter valued at about $40,000. Finally, Hantz Financial Services Inc. boosted its position in shares of Cytokinetics by 2,872.7% in the 2nd quarter. Hantz Financial Services Inc. now owns 1,308 shares of the biopharmaceutical company's stock valued at $43,000 after purchasing an additional 1,264 shares during the period.
About Cytokinetics
(
Get Free Report)
Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.
The company's most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
